Semaglutide
8
5
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
63%
5 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Semaglutide Treatment in Type 1 Diabetes
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
Subcutaneous Semaglutide in Systemic Scleroderma
The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity